Klin Onkol 2009; 22(6): 268-272.
Summary
Aromatase inhibitors are effective and well tolerated drugs in the endocrine therapy of estrogen‑
receptor positive breast cancer in postmenopausal women. Questions remain about the
long‑term side effects and safety profile of aromatase inhibitors. The results of ongoing studies
may indicate the role of aromatase inhibitors in the prevention of breast cancer. The effectiveness
and safety of aromatase inhibitor monotherapy in premenopausal breast cancer patients is
unknown, so this is an area of future exploration. Our results in the chemoprevention of mammary
carcinogenesis in female rats pointed to the potential favourable effects of aromatase inhibitors
– anastrozole and letrozole in premenopausal women affected by breast cancer.
